Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

VIR – Vir Biotechnology, Inc.

Vir Biotechnology, Inc.
VIR
$5.53
Name : Vir Biotechnology, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $758,400,832.00
EPSttm : -3.83
finviz dynamic chart for VIR
Vir Biotechnology, Inc.
$5.53
4.73%
$0.25

Float Short %

11.56

Margin Of Safety %

Put/Call OI Ratio

0.55

EPS Next Q Diff

-0.07

EPS Last/This Y

0.46

EPS This/Next Y

0.31

Price

5.52

Target Price

32

Analyst Recom

1.56

Performance Q

-54.3

Relative Volume

0.85

Beta

1.4

Ticker: VIR




23 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-03-12VIR7.340.630.1415072
2025-03-13VIR7.010.630.0615089
2025-03-14VIR7.140.600.3014964
2025-03-17VIR7.010.611.6515013
2025-03-18VIR6.930.624.4015113
2025-03-19VIR6.950.620.6115134
2025-03-20VIR6.870.621.9015234
2025-03-21VIR6.940.571.6515432
2025-03-24VIR7.210.770.246595
2025-03-25VIR6.950.752.516812
2025-03-26VIR6.610.750.006947
2025-03-27VIR6.680.750.046955
2025-03-28VIR6.70.730.006927
2025-03-31VIR6.490.610.077676
2025-04-01VIR6.180.590.387870
2025-04-02VIR6.490.590.007871
2025-04-03VIR5.960.591.307885
2025-04-04VIR5.580.580.327928
2025-04-07VIR5.510.580.657955
2025-04-08VIR5.20.590.457980
2025-04-09VIR5.720.551.407754
2025-04-10VIR5.270.550.337813
2025-04-11VIR5.530.550.637806
DateSymbolLastP/C OIP/C VolTotal OI
23 items Current Page1 of 1




23 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-03-12VIR7.33-75.7- -3.37
2025-03-13VIR7.00-75.7- -3.37
2025-03-14VIR7.15-75.7- -3.37
2025-03-17VIR7.01-75.7- -3.37
2025-03-18VIR6.93-75.7- -3.37
2025-03-19VIR6.95-75.7- -3.37
2025-03-20VIR6.87-75.7- -3.37
2025-03-21VIR6.94-75.7- -3.37
2025-03-24VIR7.20-75.7- -3.37
2025-03-25VIR6.95-75.7- -3.37
2025-03-26VIR6.59-75.7- -3.37
2025-03-27VIR6.68-75.7- -3.37
2025-03-28VIR6.70-75.7- -3.37
2025-03-31VIR6.48-75.7- -3.37
2025-04-01VIR6.18-75.7- -3.37
2025-04-02VIR6.48-75.7- -3.37
2025-04-03VIR5.96-75.7- -3.37
2025-04-04VIR5.57-75.7- -3.37
2025-04-07VIR5.51-75.7- -3.37
2025-04-08VIR5.19-75.7- -3.37
2025-04-09VIR5.72-75.7- -3.37
2025-04-10VIR5.28-75.7- -3.37
2025-04-11VIR5.52-75.7- -3.37
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
23 items Current Page1 of 1




23 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-03-12VIR-0.170.788.89
2025-03-13VIR-0.170.788.89
2025-03-14VIR-0.170.788.89
2025-03-17VIR-0.170.798.89
2025-03-18VIR-0.170.798.89
2025-03-19VIR-0.170.798.89
2025-03-20VIR-0.170.798.89
2025-03-21VIR-0.170.798.89
2025-03-24VIR-0.170.778.89
2025-03-25VIR-0.170.778.89
2025-03-26VIR-0.170.779.02
2025-03-27VIR-0.170.779.02
2025-03-28VIR-0.170.779.02
2025-03-31VIR-0.170.819.02
2025-04-01VIR-0.170.819.02
2025-04-02VIR-0.170.819.02
2025-04-03VIR-0.170.819.02
2025-04-04VIR-0.330.819.02
2025-04-07VIR-0.330.819.02
2025-04-08VIR-0.330.819.02
2025-04-09VIR-0.330.819.02
2025-04-10VIR-0.330.8111.56
2025-04-11VIR-0.330.8111.56
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
23 items Current Page1 of 1

Last Quarter Act. EPS

-0.76

Avg. EPS Est. Current Quarter

-0.84

Avg. EPS Est. Next Quarter

-0.83

Insider Transactions

-0.33

Institutional Transactions

0.81

Beta

1.4

Average Sales Estimate Current Quarter

8

Average Sales Estimate Next Quarter

6

Fair Value

Quality Score

37

Growth Score

43

Sentiment Score

25

Actual DrawDown %

96.1

Max Drawdown 5-Year %

-93.7

Target Price

32

P/E

Forward P/E

PEG

P/S

10.22

P/B

0.66

P/Free Cash Flow

EPS

-3.83

Average EPS Est. Cur. Y​

-3.37

EPS Next Y. (Est.)

-3.06

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-703.4

Relative Volume

0.85

Return on Equity vs Sector %

-64.9

Return on Equity vs Industry %

-52.1

EPS 1 7Days Diff

0.4

EPS 1 30Days Diff

0.37

EBIT Estimation

Vir Biotechnology, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 408
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
stock quote shares VIR – Vir Biotechnology, Inc. Stock Price stock today
news today VIR – Vir Biotechnology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch VIR – Vir Biotechnology, Inc. yahoo finance google finance
stock history VIR – Vir Biotechnology, Inc. invest stock market
stock prices VIR premarket after hours
ticker VIR fair value insiders trading